Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function
Effects of Treatment of Ascites by the ALFApump System on Renal and Circulatory Function in Patients With Cirrhosis and Recurrent or Refractory Ascites
Sponsor: Sequana Medical N.V.
Listed as NCT01438970, this PHASE2 trial focuses on Cirrhosis, Liver and Refractory Ascites and remains ongoing. Sponsored by Sequana Medical N.V., it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Nov 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Sep 2018 — Nov 2019 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Sep 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sequana Medical N.V.
For direct contact, visit the study record on ClinicalTrials.gov .